{
    "clinical_study": {
        "@rank": "122918", 
        "brief_summary": {
            "textblock": "RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the\n      laboratory. Antineoplastons may inhibit the growth of cancer cells.\n\n      PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating\n      patients with recurrent or refractory mixed gliomas."
        }, 
        "brief_title": "Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas", 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Nervous System Neoplasms", 
                "Central Nervous System Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and effectiveness of antineoplastons A10 and AS2-1 in patients\n           with incurable progressive, recurrent, or persistent mixed gliomas following standard\n           therapy.\n\n        -  Assess the response, tolerance to, and side effects of this regimen in these patients.\n\n      OUTLINE: This is an open label study.\n\n      Patients receive gradually escalating doses of antineoplaston A10 and antineoplaston AS2-1\n      by intravenous injection 6 times daily until the maximum tolerated dose is reached.\n      Treatment continues in the absence of toxicity and disease progression.\n\n      Tumors are measured every 2 months for 1 year, every 3 months for the second year, every 3-4\n      months for the third and fourth years, every 4-6 months for the fifth year, then annually\n      thereafter.\n\n      PROJECTED ACCRUAL: This study will accrue 20-40 patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed incurable primary mixed glioma that is progressive,\n             persistent, or recurrent following initial standard therapy, including radiation\n             therapy\n\n          -  Measurable disease by CT scan or MRI\n\n          -  Tumor must be at least 5 mm\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  At least 2 months\n\n        Hematopoietic:\n\n          -  WBC at least 2000/mm3\n\n          -  Platelet count at least 50,000/mm3\n\n        Hepatic:\n\n          -  No hepatic insufficiency\n\n          -  Bilirubin no greater than 2.5 mg/mL\n\n          -  SGOT and SGPT no greater than 5 times upper limit of normal\n\n        Renal:\n\n          -  No renal insufficiency\n\n          -  Creatinine no greater than 2.5 mg/mL\n\n          -  No history of renal conditions that contraindicate high dosages of sodium\n\n        Cardiovascular:\n\n          -  No known chronic heart failure\n\n          -  No uncontrolled hypertension\n\n          -  No history of congestive heart failure\n\n          -  No other cardiovascular conditions that contraindicate high dosages of sodium\n\n        Pulmonary:\n\n          -  No severe lung disease\n\n          -  No severe chronic obstructive pulmonary disease\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for 4 weeks after study\n\n          -  No other severe medical illness\n\n          -  No nonmalignant systemic disease\n\n          -  No active infection\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since immunotherapy\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)\n\n        Endocrine therapy:\n\n          -  Concurrent corticosteroids allowed\n\n        Radiotherapy:\n\n          -  At least 8 weeks since prior radiotherapy (unless there is evidence of disease\n             progression)\n\n        Surgery:\n\n          -  Fully recovered from prior surgery\n\n        Other:\n\n          -  Prior cytodifferentiating agent allowed\n\n          -  No prior antineoplaston therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003473", 
            "org_study_id": "CDR0000066510", 
            "secondary_id": "BC-BT-18"
        }, 
        "intervention": [
            {
                "intervention_name": "antineoplaston A10", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "antineoplaston AS2-1", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult mixed glioma"
        ], 
        "lastchanged_date": "June 9, 2009", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/BC-BT-18"
        }, 
        "location": {
            "contact": {
                "email": "info@burzynskiclinic.com", 
                "last_name": "Stanislaw R. Burzynski, MD, PhD", 
                "phone": "713-335-5697"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77055-6330"
                }, 
                "name": "Burzynski Clinic"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Mixed Glioma", 
        "overall_official": {
            "affiliation": "Burzynski Research Institute", 
            "last_name": "Stanislaw R. Burzynski, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate based on tumor measurements taken at 12 weeks", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003473"
        }, 
        "responsible_party": {
            "name_title": "Stanislaw R. Burzynski", 
            "organization": "Burzynski Clinic"
        }, 
        "secondary_outcome": {
            "measure": "Survival at 1, 2, and 5 years from the start of treatment", 
            "safety_issue": "No"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Burzynski Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 1996", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2009"
    }, 
    "geocoordinates": {
        "Burzynski Clinic": "29.76 -95.369"
    }
}